Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination

被引:0
作者
Petrelli, Fiorella [1 ]
Giannini, Daiana [1 ]
Pucci, Celestino [1 ]
Del Corso, Isabella [1 ]
Rocchi, Valeria [1 ]
Dolcher, Maria Pia [1 ]
Pieve, Giulio [2 ]
Pratesi, Federico [1 ]
Migliorini, Paola [1 ]
Puxeddu, Ilaria [1 ]
机构
[1] Pisa Univ, Dept Clin & Expt Med, Immunoallergol Unit, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Direz Med Presidio, Pisa, Italy
关键词
COVID-19; Vaccine; Allergy; Skin test; Polyethylene glycol; Polysorbates; BNT162B2;
D O I
10.1159/000526764
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Introduction: Immediate and delayed hypersensitivity reactions (HSR) to COVID-19 vaccines are rare adverse events that need to be prevented, diagnosed, and managed in order to guarantee adherence to the vaccination campaign. The aims of our study were to stratify the risk of HSR to COVID-19 vaccines and propose alternative strategies to complete the vaccination. Methods: 1,640 subjects were screened for vaccinal eligibility, according to national and international recommendations. Among them, we enrolled for allergy workup 152 subjects, 43 with HSR to COVID-19 vaccines and 109 at high risk of HSR to the first dose. In vivo skin tests with drugs and/or vaccines containing PEG/polysorbates were performed in all of them, using skin prick test and, when negative, intradermal tests. In a subgroup of patients resulted negative to the in vivo skin tests, the programmed dose of COVID-19 vaccine (Pfizer/BioNTech) was administered in graded doses regimen, and detection of neutralizing anti-spike antibodies was performed in these patients after 4 weeks from the vaccination, using the SPIA method. Results: Skin tests for PEG/polysorbates resulted positive in only 3% (5/152) of patients, including 2 with previous HSR to COVID-19 vaccines and 3 at high risk of HSR to the first dose. Among the 147 patients with negative skin tests, 97% (143/147) were eligible for vaccination and 87% (124/143) of them received safely the programmed COVID-19 vaccine dose. Administration of graded doses of Pfizer/BioNTech vaccine were well tolerated in 17 out of 18 patients evaluated; only 1 developed an HSR during the vaccination, less severe than the previous one, and all developed neutralizing anti-spike antibodies after 4 weeks with values comparable to those subjects who received the vaccine in unfractionated dose. Conclusion: On the whole, the usefulness of the skin tests for PEG/polysorbates seems limited in the diagnosis of HSR to COVID-19 vaccines. Graded doses regimen (Pfizer/BioNTech) is a safe and effective alternative strategy to complete the vaccinal course.
引用
收藏
页码:54 / 62
页数:9
相关论文
共 34 条
  • [1] AAIITO-SIAAIC, 2022, LIN IND INQ GEST PAZ
  • [2] AAIITO-SIAAIC, 2021, LIN IND GEST PART DE
  • [3] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [4] mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach
    Banerji, Aleena
    Wickner, Paige G.
    Saff, Rebecca
    Stone, Cosby A.
    Robinson, Lacey B.
    Long, Aidan A.
    Wolfson, Anna R.
    Williams, Paul
    Khan, David A.
    Phillips, Elizabeth
    Blumenthal, Kimberly G.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (04) : 1423 - 1437
  • [5] Allergy to COVID-19 vaccines: A current update
    Cabanillas, Beatriz
    Novak, Natalija
    [J]. ALLERGOLOGY INTERNATIONAL, 2021, 70 (03) : 313 - 318
  • [6] Successful administration of second dose of BNT162b2 COVID-19 vaccine in two patients with potential anaphylaxis to first dose
    Cahill, Julia A.
    Kan, Manstein
    [J]. ALLERGY, 2022, 77 (01) : 337 - 338
  • [7] World allergy organization anaphylaxis guidance 2020
    Cardona, Victoria
    Ansotegui, Ignacio J.
    Ebisawa, Motohiro
    El-Gamal, Yehia
    Fernandez Rivas, Montserrat
    Fineman, Stanley
    Geller, Mario
    Gonzalez-Estrada, Alexei
    Greenberger, Paul A.
    Sanchez Borges, Mario
    Senna, Gianenrico
    Sheikh, Aziz
    Kase Tanno, Luciana
    Thong, Bernard Y.
    Turner, Paul J.
    Worm, Margitta
    [J]. WORLD ALLERGY ORGANIZATION JOURNAL, 2020, 13 (10):
  • [8] Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI [10.1056/NEJMra2035343, 10.1056/NEJMc2100766]
  • [9] Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
    Garvey, Lene H.
    Nasser, Shuaib
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 2021, 126 (03) : E106 - E108
  • [10] May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?
    Giavina-Bianchi, Pedro
    Kalil, Jorge
    [J]. WORLD ALLERGY ORGANIZATION JOURNAL, 2021, 14 (04):